Navigation Links
Immunotherapeutic in Medical News

Light Sciences Oncology Announces Results of Study on Immunotherapeutic Mechanism of Aptocine(TM), a Novel Light-Activated Drug Therapy for Cancer

Preclinical Study is Subject of Upcoming ASCO Presentation BELLEVUE, Wash., May 18 /PRNewswire/ -- Light Sciences Oncology, Inc. (LSO) today announced that a new preclinical study has yielded evidence that the company's novel light-activated drug Aptocine(TM) (formerly Litx(TM)) may enhance a...

China Biopharma to Introduce an Immunotherapeutic Vaccine into China

China Biopharma, Inc., has reached a tentative agreement with Delmont Laboratory to introduce its immunotherapeutic vaccine Staphage Lysate that treats diseases of staphylococcal infection . According to this initial agreement, Delmont Laboratory will supply bulk materials and China Biopharma will ...

Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer

...ncer patients." About Bellicum Pharmaceuticals Bellicum Pharmaceuticals, Inc. is developing next generation therapeutic vaccines and other immunotherapeutic approaches for the treatment of cancer and chronic infectious diseases. Bellicum's novel approach is to utilize precise knowledge of the signaling pat...

Promising Therapy for Prostate Cancer

...-- An experimental drug therapy appears to have helped destroy allegedly inoperable prostate cancer in two patients in a clinical trial. Use of the immunotherapeutic agent MDX-010, or ipilimumab, in combination with standard hormone and radiation treatments helped eliminate the aggressive tumors, which had already ...

Mayo researchers: Dramatic outcomes in prostate cancer study

...g therapy that was used in combination with standardized hormone treatment and radiation therapy. The men were participating in a clinical trial of an immunotherapeutic agent called MDX-010 or ipilimumab. In these two cases, physicians say the approach initiated the death of a majority of cancer cells and caused the t...

ASCO Research Foundation Grant Will Support Study of Peregrine's Bavituximab in Lung Cancer

...d Steven W. King, president and CEO of Peregrine. "This clinical study should help us to better understand the biological effects of this new class of immunotherapeutic agents and generate data that will help guide the future clinical development and use of bavituximab." Dr. Gerber, assistant professor at the Har...

Ortho Biotech Oncology Research & Development Announces Collaboration with National Cancer Institute to Develop Novel Cell Therapies to Treat Cancer

... re-administered. Researchers at Ortho Biotech Oncology Research & Development independently developed a different and proprietary adoptive immunotherapeutic approach that uses tumor antigens and other materials to stimulate T cells from a patient's blood to become Cytotoxic T Lymphocytes (CTLs), which reco...

Study to Investigate AHCC and the Swine Flu Virus

...SA. "The animal study published by my group in the recent issue of Journal of Nutrition suggested that dietary supplementation with AHCC may be immunotherapeutic for the West-Nile Virus potentially susceptible populations." said Tian Wang, Assistant Professor at the Departments of Microbiology, Immunology and ...

Biotech company cofounded by BIDMC scientists targets natural killer T-cells

...[together with the company's third cofounder Brian Wilson, MD, PhD, of Massachusetts General Hospital] have extensive expertise in the applications of immunotherapeutic agents to human disease," explains Mark Chalek, Chief of Business Ventures at BIDMC. "Their research has helped to establish the important role of NKT...

CEL-SCI Announces Exclusive Licensing Agreement for Cancer Drug Multikine(R) for Republic of South Africa

...ne, a patented defined mixture of naturally derived cytokines, is the first immunotherapeutic agent in a new class of drugs called "Immune SIMULATORS". Immune SIMULATORS...nger anti-tumor attack on multiple fronts. Multikine is also the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer...
Immunotherapeutic in Medical Technology

Vical Receives NIH Grant for an Immunotherapeutic Herpes DNA Vaccine; Herpes Experts at University of Washington and University of Texas to Conduct Preclinical Development

SAN DIEGO, April 3, 2008 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL ) today announced that it has been awarded a two-year, $2.0 million Phase II Small Business Technology Transfer (STTR) grant from the U.S. National Institute of Allergy and Infectious Diseases (NIAID) of the N...

USC Keck School of Medicine's Dr. Alan Epstein Receives Prestigious National Cancer Institute RAID Award for Breakthrough IL-2 Molecule Therapeutic

... of melanoma in situ. The current lifetime risk for developing invasive melanoma is 1 case per 60 Americans. Currently, IL-2 is the only FDA approved immunotherapeutic agent. But while the current therapy provides unparalleled recovery for certain cancer patients, the application of IL-2 is severely limited by ...

AlphaVax Announces Promising Results in Melanoma Studies

...ingle intervention we have seen in this model." "We are excited by the results obtained in the studies conducted by Dr. Wolchok's group at MSKCC. immunotherapeutic intervention with a novel vaccine vector such as ours may prove beneficial as a treatment strategy for patients with melanoma, and we hope to translat...

Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting

...ses refractory to CD20-targeted therapies. Abstract: 5465 Presentation Title: CD79BxDR SCORPION molecule: a single-chain, bispecific immunotherapeutic with potent in vitro activity against B-cell lymphoma Presentation Time: Wednesday, April 22, 2009, 8 a.m.-noon Location: Hall B-F, Poster Sec...

CEL-SCI Corporation Releases Letter to Shareholders

...ne, a patented defined mixture of naturally derived cytokines, is the first immunotherapeutic agent in a new class of drugs called "Immune SIMULATORS". Immune SIMULATOR...nger anti-tumor attack on multiple fronts. Multikine is also the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer...

Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey

...les and marketing of the company's Allovectin-7(R) immunotherapeutic product candidate in Turkey and the Turkish Republ...d a large Phase 2 trial evaluating Allovectin-7(R) immunotherapeutic as a single agent for patients with Stage III or I...h the FDA for a Phase 3 trial (the Allovectin-7(R) immunotherapeutic for Metastatic Melanoma, or AIMM trial) for certai...

CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine

...anted orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck. Multikine is also the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer. It is administered prior to any other cancer therapy because that is the ...

CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect

...ine, a patented defined mixture of naturally derived cytokines is the first immunotherapeutic agent in a new class of drugs called "Immune SIMULATORS." Immune SIMULATORS...tronger anti-tumor attack on multiple fronts. Multikine is also the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer...

CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008

...ne, a patented defined mixture of naturally derived cytokines, is the first immunotherapeutic agent in a new class of drugs called "Immune SIMULATORS". Immune SIMULATORS...tronger anti-tumor attack on multiple fronts. Multikine is also the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer...

Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial

...y AnGes. Vical is conducting the Allovectin-7(R) immunotherapeutic for Metastatic Melanoma, or AIMM trial, a Phase 3 ...otal trial of the company's Allovectin-7(R) cancer immunotherapeutic as first-line therapy in chemotherapy-naive patien...d a large Phase 2 trial evaluating Allovectin-7(R) immunotherapeutic as a single agent for patients with Stage III or I...
Immunotherapeutic in Biological News

Another JDRF partner moves research forward with collaboration agreement for diabetes treatment

...on agreement with Genentech, Inc., a wholly owned member of the Roche Group, to further develop and potentially commercialize a novel antigen-specific immunotherapeutic designed to reverse the immune response that causes type 1 diabetes. To date, JDRF has awarded more than $29 million in research funding to 25 co...

When acute hepatitis develops into chronic hepatitis

... The doctor thus has an opportunity to improve his diagnosis with so-called "marker genes" and to improve his treatment of the patients with targeted, immunotherapeutic measures", says Robert Geffers, who conducted the gene analysis of the blood tests. ...

Bayhill Therapeutics and the Juvenile Diabetes Research Foundation announce research collaboration

...se I/II human clinical trial of BHT-3021, a DNA vaccine to reverse the immune response that causes type 1 diabetes. BHT-3021 is an antigen-specific immunotherapeutic DNA vaccine designed to reverse the underlying autoimmune disease process in diabetes, and slow down or halt further loss of pancreatic beta cell func...

Mechanisms involved with tumor relapse identified

...interferon gamma as one of the signaling proteins involved with tumor relapse. The findings may help researchers develop tailored vaccines and other immunotherapeutic strategies to fight a number of cancers. Immunotherapy involves the manipulation of the immune system ?by introducing an antibody or lymphocytes, or i...

Temple University Hospital investigates treatment for cervical dysplasia

...fected with HPV who have moderate to severe cervical dysplasia, a precancerous condition," explained Hernandez. Amolimogene is an investigational immunotherapeutic from MGI PHARMA, Inc. that is currently being evaluated in a pivotal phase 2 clinical program in multiple centers in the U.S., including Philadelphia....

Innovative movies show real-time immune-cell activity within tumors

...ular requirements for T cell migration and T cell-tumor cell interactions. We should then be able to use results from this research to further improve immunotherapeutic strategies against cancer in patients." ...

Faster immune system testing set to improve poultry quality

...atia had the basic idea twenty years ago but he had to wait for advances in molecular biology. "The test is ready but we need to develop the companion immunotherapeutic to convince an animal health company to take it on," explains project leader Dr William Ragland of Zagreb Biotek in Croatia. He had hoped that there w...

Researchers discover new tumor defense system

...gy journal. Several forms of anti-cancer therapy rely on what is known as immunotherapeutic anti-cancer strategies, therapies that encourage the body's natural defenses, such as cytotoxic T lymphocytes, to aid in destroying tumors. However, immunotherapeutic methods are often not effective at removing established tumors for a number...
Immunotherapeutic in Biological Technology

Studies Presented at International Conference on Alzheimer's Disease Reveal Substantial Economic Costs and Caregiver Burden Associated with Alzheimer's Disease

...yeth Collaboration The Alzheimer's Immunotherapy Program (AIP) is a collaboration between Elan and Wyeth to research, develop, and commercialize immunotherapeutic approaches that may be used to treat and possibly prevent the onset of Alzheimer's disease. The AIP is committed to researching the burden of care an...

Celsense, Inc Receives NIH Grant to Translate Cell Imaging Technology for Clinical Use

...reliminary data critically important for improving immunotherapeutic delivery strategies in metastatic colorectal (CRC)...which is actively conducting clinical trials using immunotherapeutic dendritic cell (DC) vaccines to treat CRC, directe...unts for approximately 150,000 new cases annually. immunotherapeutic interventions using live-cell DC vaccines may pote...

The Institut Pasteur and Merieux Alliance Take First Step Towards a Long-Term Research Partnership in the Field of Infectious Diseases

...roteins; - Transgene, based in Strasbourg (France), which is 55%-controlled. Dedicated to the development of therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases; - ABL Inc (Advanced BioScience Laboratories), based in Washington D.C. (US), which is 100%-own...

MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 4, 2009

...s diabetes pipeline includes AFRESA(R), an ultra rapid-acting insulin and MKC253, an inhaled formulation of human GLP-1. MannKind also has two cancer immunotherapeutic products in clinical development. MannKind maintains a website at http://www.mannkindcorp.com to which the company regularly posts copies of its pr...

Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting

...rgeted therapies. (Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO ) CD79BxDR SCORPION molecule: a single-chain, bispecific immunotherapeutic with potent in vitro activity against B-cell lymphoma B-cell depletion with agents such as Rituxan(R) has proven successful in the treatment ...

Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics

...t transformation of colonic epithelial cells, and has profound expertise in immunotherapeutic targets CEA and EpCAM, which are being targeted by Micromet's product candi...s principal and co-investigator in numerous clinical trials exploring novel immunotherapeutic approaches. He has particular expertise in the role T cells play in cancer ...

MannKind Submits NDA for AFRESA for Treatment of Diabetes

...s pipeline includes AFRESA(R), an ultra rapid-acting prandial insulin and MKC253, an inhaled formulation of human GLP-1. MannKind also has two cancer immunotherapeutic products in clinical development. MannKind maintains a website at http://www.mannkindcorp.com to which the company regularly posts copies of its pr...

Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors

...s proprietary SL052 for photodynamic therapy (PDT) used in combination with immunotherapeutic agents in solid tumor animal models. The study, conducted by Dr. Mladen Kor...ncouver, demonstrated that SL052 increased the potency and effectiveness of immunotherapeutic agents when used in combination with SL052 PDT. The results also confirme...

PDS Biotechnology Corporation Finalizes Commercial Licensing Agreement with Merck Eprova AG to Utilize Merck Eprova's Enantiomers of DOTAP Chloride in Immunotherapies

...samune(TM) nanoparticle technology. PDS Biotechnology will own the intellectual property rights to products incorporating the chiral DOTAP lipids for immunotherapeutic applications. Versamune(TM)-HPV is an immunotherapy drug which has demonstrated significant promise in curing HPV infection and HPV-related can...

Cancer Advances Acquires the Intellectual Property for a Suite of Products that Enhance the Immune System in Treatment of Gastric, Pancreatic, and Colorectal Cancers

...ers. Cancer Advances will be seeking additional funding for the company as well as potential development partners. About PAS PAS is an active immunotherapeutic that induces antibodies against the hormone, gastrin 17 (G17), and its precursor, (gly)G17, of which there is extensive published evidence for a centr...
Immunotherapeutic in Biological Dictionary

Antigen

... blog. Antigen Express is a platform and product-based company developing proprietary ... GENEREX PUBLISHES RESULTS FROM PRE-CLINICAL STUDIES ON immunotherapeutic VACCINE ... Antigen - Definition of Antigen at Dictionary.com a free online dictionary with ... Link To antigen . find Research Antibodies ......
Other Tags
(Date:7/13/2014)... The North American water storage systems market is estimated to ... 2018, at a CAGR of 21.0%, from 2013 to 2018. ... pace in North America. The U.S. is experiencing high growth ... storage and collection, and the increased spending on modernization and ... healthy rate in Canada, and is rising at a rapid ...
(Date:7/13/2014)... According to a new market research ... Component (processor, GPU, DSP, connectivity), Technology Node (45nm-5nm), ... - Forecast and Analysis to 2014-2020", published by ... Market is expected to reach $61.70 Billion by ... 2014 to 2020. , Browse 71 market data ...
(Date:7/13/2014)... Athletes with a certain genetic make-up ... according to research presented today at the American Orthopaedic ... The research marks the first of its kind investigating ... physical events that occur after a head injury. ... in the (GT)n genotype were four times more likely ...
(Date:7/13/2014)... Fadhits.com is popular among worldwide women. Its lace wedding ... the company has announced its new selection of elegant ... these outfits are available at discounted prices (from 25 ... is now offering similar discounts for many other wonderful ... other designs for sale, including flower girl dresses, wedding ...
(Date:7/13/2014)... 2014 Wright & Schulte LLC has ... scheduled in July of 2015, in U.S. District Court, ... in the discovery process in the South Carolina ... presiding over the multidistrict litigation (MDL). The complaints pending ... individuals who allege that they took the statin medication ...
Breaking Medicine News(10 mins):Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 2Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Fadhits.com Announces a Special Offer on Elegant Quinceanera Dresses 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4
(Date:7/11/2014)... exists that cannabinoid receptor type 1 can ... influx, and reduce neurotransmitter release. However, some ... can increase extracellular Ca2+ influx and increase ... team, Tongji Hospital Affiliated to Tongji Medical ... China used whole cell voltage-clamp and calcium ...
(Date:7/10/2014)... SPRINGS, Colo. , June 27, 2014 /PRNewswire/ ... that the National Institute of Standards and Technology ... 10 of its academic research and forensic science ... (FSSB).  The Board is an element of the ... AAFS members are among the first appointments made ...
(Date:7/10/2014)... , July 2, 2014 It is a ... announce the appointment of the world-renowned Thoracic and Cardiovascular ... Directors. Dr. Ginsburg, with over 34 years ... Presbyterian Hospital and Good Samaritan Regional Medical Center. Dr. ... the late 1980,s and is considered an expert in ...
Breaking Biology News(10 mins):Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 3Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2
Other Contents